Your browser doesn't support javascript.
loading
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Diab, Adi; Gogas, Helen; Sandhu, Shahneen; Long, Georgina V; Ascierto, Paolo A; Larkin, James; Sznol, Mario; Franke, Fabio; Ciuleanu, Tudor E; Pereira, Caio; Muñoz Couselo, Eva; Bronzon Damian, Fernanda; Schenker, Michael; Perfetti, Aldo; Lebbe, Celeste; Quéreux, Gaëlle; Meier, Friedegund; Curti, Brendan D; Rojas, Carlos; Arriaga, Yull; Yang, Haisu; Zhou, Ming; Ravimohan, Shruthi; Statkevich, Paul; Tagliaferri, Mary A; Khushalani, Nikhil I.
Afiliação
  • Diab A; Melanoma Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Gogas H; First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Sandhu S; Department of Medical Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, VIC, Australia.
  • Long GV; Melanoma Institute Australia, Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia.
  • Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics Department, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
  • Larkin J; Medical Oncology, The Royal Marsden Hospital, London, United Kingdom.
  • Sznol M; Medical Oncology, Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital Yale New Haven Health, New Haven, CT.
  • Franke F; Medical Oncology, Oncosite Centro de Pesquisa Clínica, Ijui, Brazil.
  • Ciuleanu TE; Medical Oncology, Institutul Prof Dr Ion Chiricuta, Cluj-Napoca, Romania.
  • Pereira C; Fundação Pio XII, Hospital de Câncer de Barretos, Barretos, Brazil.
  • Muñoz Couselo E; Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Bronzon Damian F; Hospital São Lucas da PUCRS, Porto Alegre, Brazil.
  • Schenker M; Sf Nectarie Oncology Center, University of Medicine and Pharmacy, Craiova, Romania.
  • Perfetti A; Clínica Adventista Belgrano, Buenos Aires, Argentina.
  • Lebbe C; AP-HP Department of Dermato-oncology and CIC, INSERM U976, Cancer Institute APHP, Nord-Université Paris Cite, Université Paris Cité, Paris, France.
  • Quéreux G; Department of Dermatology, CIC 1413, de Cancéro-Dermatologie-CIC Biothérapie Nantes, Nantes University Hospital, Nantes, France.
  • Meier F; Skin Cancer Center, National Center for Tumor Diseases, University Cancer Centre Dresden, Dresden, Germany.
  • Curti BD; Department of Dermatology, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Rojas C; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR.
  • Arriaga Y; Medical Oncology, Bradford Hill Clinical Research Center, Santiago, Chile.
  • Yang H; Medical Oncology, Bristol Myers Squibb, Princeton, NJ.
  • Zhou M; Medical Oncology, Bristol Myers Squibb, Princeton, NJ.
  • Ravimohan S; Medical Oncology, Bristol Myers Squibb, Princeton, NJ.
  • Statkevich P; Translational Medicine, Bristol Myers Squibb, Princeton, NJ.
  • Tagliaferri MA; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ.
  • Khushalani NI; Clinical Development Department, Nektar Therapeutics, San Francisco, CA.
J Clin Oncol ; 41(30): 4756-4767, 2023 10 20.
Article em En | MEDLINE | ID: mdl-37651676
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nivolumabe / Melanoma Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nivolumabe / Melanoma Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article